Genomic Profiling of Biliary Tract Cancers and Implications for Clinic

Discussion Board › Forums › New Developments › Genomic Profiling of Biliary Tract Cancers and Implications for Clinic

Viewing 2 posts - 1 through 2 (of 2 total)
  • Author
    Posts
  • September 25, 2016 at 10:07 pm #44776
    marions
    Moderator

    Thanks, Gavin.

    Quote: KRAS and p53 mutations are associated with an aggressive disease prognosis while FGFR mutations may signify a relatively indolent disease course of intrahepatic cholangiocarcinoma.

    FGFR and IDH mutations have promising agents in clinical trials at this time.

    An estimated 10-15 % of cholangiocarcinomas have DNA repair mutations and may be candidates for immune therapies with checkpoint inhibitors.

    September 25, 2016 at 5:03 pm #4386
    gavin
    Moderator

    Genomic Profiling of Biliary Tract Cancers and Implications for Clinical Practice.

    http://www.ncbi.nlm.nih.gov/pubmed/27658789

  • Author
    Posts
Viewing 2 posts - 1 through 2 (of 2 total)
  • The forum ‘New Developments’ is closed to new topics and replies.